George Demetri, MD, Director of the Ludwig Center and Sarcoma Center at Dana-Farber Cancer Institute and Harvard Medical School in Boston, explains the side effects associated with the oral multikinase inhibitor regorafenib, which targets the KIT and PDGFRA mutations while also blocking angiogenesis through dual VEGF receptor inhibition.
To find out more, visit [ Ссылка ]
